Related Experiment Video
Updated: Jul 7, 2026

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
Published on: September 14, 2021
TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule
Fabio Manzo1, Angela Nebbioso, Marco Miceli
1Dipartimento di Patologia Generale, Seconda Università degli Studi di Napoli, Italy.
Abstract:
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor super-family and signals via two death receptors, TRAIL-R1 and TRAIL-R2, and two decoy receptors, TRAIL-R3 and TRAIL-R4, differently expressed in normal and cancer cells. TRAIL is mainly studied for its capacity to induce apoptosis preferentially in cancer cells. TRAIL is expressed in a variety of human tissues, in particular in the lymphoid system, suggesting a strong physiological role in the innate immunity. This review will focus on TRAIL gene structure and regulation, protein folding, tissue expression and molecular signalling. Finally, the potential use of TRAIL as anticancer treatment alone or in combination therapy as well as the use of drugs which signal via TRAIL and its receptors will be analyzed.
Insights
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces cancer cell death and plays a role in immunity. This review explores TRAIL
Area of Science:
- Molecular biology
- Immunology
- Cancer research
Background:
- Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a key mediator of programmed cell death.
- TRAIL interacts with death receptors (TRAIL-R1/R2) and decoy receptors (TRAIL-R3/R4), with differential expression in normal versus cancer cells.
- TRAIL's expression in the lymphoid system suggests a significant role in innate immunity.
Purpose of the Study:
- To provide a comprehensive review of TRAIL's biological functions and therapeutic potential.
- To analyze TRAIL gene structure, regulation, protein folding, tissue expression, and molecular signaling pathways.
- To evaluate TRAIL's application in cancer treatment, both as a monotherapy and in combination therapies.
Main Methods:
- Literature review and analysis of existing research on TRAIL.
- Examination of TRAIL gene structure, protein characteristics, and signaling mechanisms.
- Assessment of preclinical and clinical data regarding TRAIL-based cancer therapies.
Main Results:
- TRAIL preferentially induces apoptosis in cancer cells.
- TRAIL exhibits a crucial role in the innate immune system.
- Differential expression of TRAIL receptors in normal and cancerous tissues is a key aspect of its function.
Conclusions:
- TRAIL holds significant promise as an anticancer therapeutic agent.
- Combination therapies involving TRAIL or TRAIL-targeting drugs may enhance treatment efficacy.
- Further research into TRAIL signaling and its receptors is warranted for optimizing cancer treatment strategies.
Related Concept Videos
TGF - β Signaling Pathway
The Extrinsic Apoptotic Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Signal Transduction: Overview
Typically, signal transduction involves three...
Amplifying Signals via Enzymatic Cascade
